$NUKK
Nukkleus Inc.

2024 Q2 Form 10-K Financial Statement

#000121390024060986 Filed on July 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q3 2023 Q1
Revenue $175.2K $0.00 $0.00
YoY Change
Cost Of Revenue $49.74K $5.486M
YoY Change -99.07% 1.31%
Gross Profit $125.5K $148.0K
YoY Change -179.41% -145.36%
Gross Profit Margin 71.61%
Selling, General & Admin $888.0K
YoY Change -39.23%
% of Gross Profit 600.19%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.186M
YoY Change -21.2%
% of Gross Profit 801.42%
Operating Expenses $1.517M $116.7K $78.38K
YoY Change 1164.27% -75.74% -83.3%
Operating Profit -$1.392M -$116.7K -$78.38K
YoY Change 1024.58% -75.74% -83.3%
Interest Expense -$9.390K -$930.00
YoY Change -90.41% -110.34%
% of Operating Profit
Other Income/Expense, Net -$224.6K -$9.394K -$925.00
YoY Change -16316.17% -90.4% -110.29%
Pretax Income -$1.616M -$126.1K -$79.31K
YoY Change 1246.87% -78.22% -82.77%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.616M -$126.1K -$79.31K
YoY Change 1220.86% -78.22% -82.77%
Net Earnings / Revenue -922.44%
Basic Earnings Per Share -$0.11 -$0.07 -$0.04
Diluted Earnings Per Share -$0.11 -$0.07 -$0.04
COMMON SHARES
Basic Shares Outstanding 14.80M shares 1.815M shares 1.817M shares
Diluted Shares Outstanding 14.34M shares 1.914M shares 1.949M shares

Balance Sheet

Concept 2024 Q2 2023 Q3 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.608M $4.464M
YoY Change -85.23% -89.28%
Cash & Equivalents $6.138K $4.608M $4.464M
Short-Term Investments
Other Short-Term Assets $135.6K $32.52K $740.00
YoY Change -37.43% -99.52%
Inventory
Prepaid Expenses
Receivables $189.2K
Other Receivables $18.50K $2.039M $0.00
Total Short-Term Assets $706.4K $4.608M $4.464M
YoY Change -84.63% -85.26% -89.32%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $391.2K $391.2K $6.602M
YoY Change -94.07% -94.07% -42.75%
Other Assets
YoY Change
Total Long-Term Assets $413.7K $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $706.4K $4.608M $4.464M
Total Long-Term Assets $413.7K $0.00 $0.00
Total Assets $1.120M $4.608M $4.464M
YoY Change -75.63% -85.26% -89.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $343.5K $138.7K $286.2K
YoY Change -26.91% -58.83% 22.28%
Accrued Expenses $579.7K
YoY Change 28.41%
Deferred Revenue
YoY Change
Short-Term Debt $4.181M $3.817M
YoY Change 20.05% 34.88%
Long-Term Debt Due $17.50K $17.50K
YoY Change
Total Short-Term Liabilities $12.13M $4.651M $4.103M
YoY Change 169.26% 21.77% 33.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $19.58K $11.57K
YoY Change -91.31% -93.41%
Total Long-Term Liabilities $1.223M $422.4K $11.57K
YoY Change 12131.33% 87.5% -93.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.13M $4.651M $4.103M
Total Long-Term Liabilities $1.223M $422.4K $11.57K
Total Liabilities $13.35M $4.671M $4.115M
YoY Change 195.75% 15.47% 27.02%
SHAREHOLDERS EQUITY
Retained Earnings -$48.99M -$8.550M -$7.966M
YoY Change 488.29% 9.06%
Common Stock $1.480K $3.880M $3.880M
YoY Change -99.96% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$12.23M -$4.669M -$4.086M
YoY Change
Total Liabilities & Shareholders Equity $1.120M $4.608M $4.464M
YoY Change -75.63% -85.26% -89.32%

Cashflow Statement

Concept 2024 Q2 2023 Q3 2023 Q1
OPERATING ACTIVITIES
Net Income -$1.616M -$126.1K -$79.31K
YoY Change 1220.86% -78.22% -82.77%
Depreciation, Depletion And Amortization $1.186M
YoY Change -21.2%
Cash From Operating Activities -$121.0K -$107.2K
YoY Change -14.04% -84.67%
INVESTING ACTIVITIES
Capital Expenditures $41.25K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 132.0K -$1.540M
YoY Change -101.3% -71.08%
NET CHANGE
Cash From Operating Activities -121.0K -$107.2K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 132.0K -$1.540M
Net Change In Cash 11.05K -$1.647M
YoY Change -99.96% 1175.39%
FREE CASH FLOW
Cash From Operating Activities -$121.0K -$107.2K
Capital Expenditures $41.25K
Free Cash Flow -$148.4K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10074952 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9771734 shares
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39341
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
38-3912845
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
525 Washington Boulevard
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Jersey City
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07310
CY2023 dei City Area Code
CityAreaCode
212
CY2023 dei Local Phone Number
LocalPhoneNumber
791-4663
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Public Float
EntityPublicFloat
7133000 usd
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14802414 shares
CY2023 dei Auditor Location
AuditorLocation
New Jersey
CY2023 dei Auditor Name
AuditorName
Marcum LLP
CY2023 dei Auditor Firm
AuditorFirmId
688
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19318 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
364023 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
672501 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2020394 usd
CY2022Q3 nukk Customer Digital Currency Assets Current
CustomerDigitalCurrencyAssetsCurrent
248214 usd
CY2023Q3 nukk Digital Assets1
DigitalAssets1
1973 usd
CY2022Q3 nukk Digital Assets1
DigitalAssets1
73415 usd
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2039274 usd
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
931136 usd
CY2023Q3 us-gaap Notes Receivable Net
NotesReceivableNet
162820 usd
CY2022Q3 us-gaap Notes Receivable Net
NotesReceivableNet
35000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
32522 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
15617 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
2928408 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
3687799 usd
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
391217 usd
CY2022Q3 us-gaap Equity Method Investments
EquityMethodInvestments
6602000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
33000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8075105 usd
CY2023Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
424217 usd
CY2022Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
14677105 usd
CY2023Q3 us-gaap Assets
Assets
3352625 usd
CY2022Q3 us-gaap Assets
Assets
18364904 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
138666 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
51712 usd
CY2023Q3 nukk Customer Custodial Cash Liabilitie
CustomerCustodialCashLiabilitie
1443011 usd
CY2022Q3 nukk Customer Custodial Cash Liabilitie
CustomerCustodialCashLiabilitie
2020717 usd
CY2022Q3 nukk Customer Digital Currency Liabilities Current
CustomerDigitalCurrencyLiabilitiesCurrent
248214 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6808749 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4514063 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
402241 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
237205 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
160926 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
170058 usd
CY2023Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
169872 usd
CY2022Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
232355 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9123465 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7474324 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
422390 usd
CY2023Q3 us-gaap Liabilities
Liabilities
9545855 usd
CY2022Q3 us-gaap Liabilities
Liabilities
7474324 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10074657 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10074657 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10074657 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10074657 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1007 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
1007 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25543048 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25172170 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31769244 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14340816 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
31959 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
58219 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-6193230 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
10890580 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3352625 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18364904 usd
CY2023 us-gaap Revenues
Revenues
21297642 usd
CY2022 us-gaap Revenues
Revenues
21513474 usd
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
21640783 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
22174870 usd
CY2023 us-gaap Gross Profit
GrossProfit
-343141 usd
CY2022 us-gaap Gross Profit
GrossProfit
-661396 usd
CY2023 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
55889 usd
CY2022 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
420186 usd
CY2023 us-gaap Professional Fees
ProfessionalFees
2423773 usd
CY2022 us-gaap Professional Fees
ProfessionalFees
4329988 usd
CY2023 us-gaap Labor And Related Expense
LaborAndRelatedExpense
822625 usd
CY2022 us-gaap Labor And Related Expense
LaborAndRelatedExpense
508471 usd
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
273711 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
264224 usd
CY2023 us-gaap Interest And Debt Expense
InterestAndDebtExpense
1179772 usd
CY2022 us-gaap Interest And Debt Expense
InterestAndDebtExpense
1454 usd
CY2023 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
449988 usd
CY2022 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
645860 usd
CY2023 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
11914322 usd
CY2022 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
4310745 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
17120080 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
10480928 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-17463221 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-11142324 usd
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-689255 usd
CY2023 us-gaap Interest Expense Other
InterestExpenseOther
1776 usd
CY2023 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
-36569 usd
CY2022 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
14078 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
34793 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-703333 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17428428 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11845657 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17428428 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-11845657 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17428428 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-11845657 usd
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
26260 usd
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-49779 usd
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17454688 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11795878 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.73
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10074657 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9771734 shares
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
9159692 usd
CY2022 nukk Stock Issued During Period Value Cost Method Investment
StockIssuedDuringPeriodValueCostMethodInvestment
6602000 usd
CY2022 nukk Stock Issued During Period Value Equity Method Investment
StockIssuedDuringPeriodValueEquityMethodInvestment
5000000 usd
CY2022 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
11237 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1913529 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-11845657 usd
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
49779 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
10890580 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
370878 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17428428 usd
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-26260 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-6193230 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17428428 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-11845657 usd
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2380115 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2690617 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
370878 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1913529 usd
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1179772 usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1454 usd
CY2023 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-3221 usd
CY2022 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
768 usd
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-689255 usd
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
7950 usd
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
887 usd
CY2023 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
11914322 usd
CY2022 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
4310745 usd
CY2023 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-273337 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-822650 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
618 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-53474 usd
CY2023 nukk Increase Decrease In Digital Assets
IncreaseDecreaseInDigitalAssets
-70913 usd
CY2022 nukk Increase Decrease In Digital Assets
IncreaseDecreaseInDigitalAssets
84241 usd
CY2023 us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
1338432 usd
CY2022 us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
-1686737 usd
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
25775 usd
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
4716 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
82366 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7276 usd
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-775511 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1560251 usd
CY2023 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-273337 usd
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-822650 usd
CY2023 nukk Increase Decrease In Due To Affiliate
IncreaseDecreaseInDueToAffiliate
2261395 usd
CY2022 nukk Increase Decrease In Due To Affiliate
IncreaseDecreaseInDueToAffiliate
323129 usd
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
165288 usd
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
66667 usd
CY2023 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
-17071 usd
CY2022 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
56006 usd
CY2023 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
1776 usd
CY2023 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-84543 usd
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
190961 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1232382 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1615606 usd
CY2023 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
1920754 usd
CY2022 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
35000 usd
CY2023 nukk Proceeds From Note Receivable Related Parties
ProceedsFromNoteReceivableRelatedParties
852651 usd
CY2023 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
41833 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1109936 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35000 usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
418316 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
418316 usd
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
231404 usd
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
-399262 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1692598 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1181344 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2384417 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1203073 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
691819 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2384417 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19318 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
364023 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
672501 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2020394 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
691819 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2384417 usd
CY2022 nukk Adjustment For Common Stock Issued In Connection With Asset Acquisition
AdjustmentForCommonStockIssuedInConnectionWithAssetAcquisition
6602000 usd
CY2022 us-gaap Stock Issued1
StockIssued1
5000000 usd
CY2022 us-gaap Supplemental Deferred Purchase Price
SupplementalDeferredPurchasePrice
11237 usd
CY2022 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
2861631 usd
CY2023 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-05-24
CY2023 us-gaap Equity Method Investment Additional Information
EquityMethodInvestmentAdditionalInformation
Jamal Khurshid and Nicholas Gregory own, directly and indirectly, approximately 40% and 10% of Jacobi, respectively. Jamal Khurshid is the Company’s chief operating officer and director and Nicholas Gregory is the Company’s director. The transactions contemplated by the Jacobi Agreement constituted a “related-party transaction” as defined in Item 404 of Regulation S-K because of Mr. Khurshid’s and Mr. Gregory’s position as beneficial owner of one or more Original Shareholders and New Jacobi Shareholders.
CY2021Q4 nukk Operating Capital
OperatingCapital
1 usd
CY2021Q4 nukk Exchange Shares Percentage
ExchangeSharesPercentage
0.04545 pure
CY2021Q4 nukk Additional Funds
AdditionalFunds
229837 usd
CY2023 nukk Working Capital Deficit
WorkingCapitalDeficit
6195000 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Use of estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material impact on the consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Significant estimates during the years ended September 30, 2023 and 2022 include the allowance for doubtful accounts, useful life of intangible assets, assumptions used in assessing impairment of long-term assets, valuation of deferred tax assets and the associated valuation allowances, valuation of stock-based compensation, and fair value of customer digital currency assets and liabilities.</span></p>
CY2023 nukk Shares Reflecting Exchange Ratio
SharesReflectingExchangeRatio
36.44532
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19318 usd
CY2023 nukk Cash Percentage
CashPercentage
1 pure
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
364023 usd
CY2022 nukk Cash Percentage
CashPercentage
1 pure
CY2022Q3 nukk Customer Digital Currency Assets Current
CustomerDigitalCurrencyAssetsCurrent
248214 usd
CY2022Q3 nukk Customer Digital Currency Liabilities Current
CustomerDigitalCurrencyLiabilitiesCurrent
248214 usd
CY2023 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
5703539 usd
CY2023 us-gaap Impairment Of Investments
ImpairmentOfInvestments
6210783 usd
CY2022 us-gaap Impairment Of Investments
ImpairmentOfInvestments
4310745 usd
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><span style="text-decoration:underline">Credit risk and uncertainties</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The Company maintains a portion of its cash in bank and financial institution deposits within U.S. that at times may exceed federally-insured limits of $250,000. The Company manages this credit risk by concentrating its cash balances, including customer custodial cash, in high quality financial institutions and by periodically evaluating the credit quality of the primary financial institutions holding such deposits. The Company may also hold cash at digital asset trading platforms and performs a regular assessment of these digital asset trading platforms as part of its risk management process. The Company has not experienced any losses in such bank accounts and believes it is not exposed to any risks on its cash in bank accounts. At September 30, 2023, the Company’s customer custodial cash balance had approximately $317,000 in excess of the federally-insured limits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">We may maintain our cash assets at financial institutions in the U.S. in amounts that may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit of $250,000. Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in response to the rapidly declining financial condition of regional banks Silicon Valley Bank (“SVB”) and Signature Bank (“Signature”), the California Department of Financial Protection and Innovation and the New York State Department of Financial Services closed SVB and Signature on March 10, 2023 and March 12, 2023, respectively, and the FDIC was appointed as receiver for SVB and Signature. In the event of a failure or liquidity issues of or at any of the financial institutions where we maintain our deposits or other assets, we may incur a loss to the extent such loss exceeds the FDIC insurance limitation, which could have a material adverse effect upon our liquidity, financial condition and our results of operations. Similarly, if our customers experience liquidity issues as a result of financial institution defaults or non-performance where they hold cash assets, their ability to pay us may become impaired and could have a material adverse effect on our results of operations, including the collection of accounts receivable and cash flows.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. A portion of the Company’s sales are credit sales which is to the customer whose ability to pay is dependent upon the industry economics prevailing in these areas; however, concentrations of credit risk with respect to trade accounts receivable is limited due to short-term payment terms. The Company also performs ongoing credit evaluations of its customers to help further reduce credit risk.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000 usd
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
637072 usd
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q3 us-gaap Investments
Investments
6210783 usd
CY2022 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
4310745 usd
CY2023Q3 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
0 usd
CY2023 us-gaap Revenues
Revenues
21297642 usd
CY2022 us-gaap Revenues
Revenues
21513474 usd
CY2023 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
55889 usd
CY2022 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
420186 usd
CY2023 nukk Foreign Currency Translation Description
ForeignCurrencyTranslationDescription
Asset and liability accounts at September 30, 2023 and 2022 were translated at 0.8199 GBP and 0.8987 GBP to $1.00, respectively, which were the exchange rates on the balance sheet dates. Asset and liability accounts at September 30, 2023 and 2022 were translated at 0.9446 EUR and 1.0221 EUR to $1.00, respectively, which were the exchange rates on the balance sheet dates. Asset and liability accounts at September 30, 2023 were translated at 1.3591 CAD to $1.00, which was the exchange rate on the balance sheet date. Equity accounts were stated at their historical rates. The average translation rate applied to the statement of operations for the years ended September 30, 2023 and 2022 was 0.8161 GBP and 0.7835 GBP to $1.00, respectively. The average translation rate applied to the statement of operations for the year ended September 30, 2023 and for the period from January 12, 2022 through September 30, 2022 was 0.9368 EUR and 0.9440 EUR to $1.00. The average translation rate applied to the statement of operations for the period from February 18, 2023 through September 30, 2023 was 1.3475 CAD to $1.00. Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rate.
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><span style="text-decoration:underline">Reclassification</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications have no effect on the previously reported financial position, results of operations and cash flows.<span> </span></span></p>
CY2023Q3 us-gaap Security Deposit
SecurityDeposit
21954 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
10568 usd
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
15617 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
32522 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
15617 usd
CY2023Q3 nukk Customer Custodial Cash
CustomerCustodialCash
672501 usd
CY2022Q3 nukk Customer Custodial Cash
CustomerCustodialCash
2020394 usd
CY2022Q3 nukk Customer Digital Currency Assets Current
CustomerDigitalCurrencyAssetsCurrent
248214 usd
CY2023Q3 nukk Customer Assets
CustomerAssets
672501 usd
CY2022Q3 nukk Customer Assets
CustomerAssets
2268608 usd
CY2023Q3 nukk Customer Custodial Cash Liabilitie
CustomerCustodialCashLiabilitie
1443011 usd
CY2022Q3 nukk Customer Custodial Cash Liabilitie
CustomerCustodialCashLiabilitie
2020717 usd
CY2022Q3 nukk Customer Digital Currency Liabilities Current
CustomerDigitalCurrencyLiabilitiesCurrent
248214 usd
CY2023Q3 nukk Customer Liabilities
CustomerLiabilities
1443011 usd
CY2022Q3 nukk Customer Liabilities
CustomerLiabilities
2268931 usd
CY2022Q3 nukk Customer Digital Currency Assets
CustomerDigitalCurrencyAssets
248214 usd
CY2022Q3 nukk Customer Digital Currency Assets Percentage
CustomerDigitalCurrencyAssetsPercentage
1 pure
CY2023Q3 nukk Digital Asset Gross
DigitalAssetGross
1973 usd
CY2023Q3 nukk Digital Assets1
DigitalAssets1
1973 usd
CY2022Q3 nukk Digital Asset Gross
DigitalAssetGross
74189 usd
CY2022Q3 nukk Digital Assets Impairment Charges
DigitalAssetsImpairmentCharges
774 usd
CY2022Q3 nukk Digital Assets1
DigitalAssets1
73415 usd
CY2023 us-gaap Utilities Operating Expense Impairments
UtilitiesOperatingExpenseImpairments
7950 usd
CY2022 us-gaap Utilities Operating Expense Impairments
UtilitiesOperatingExpenseImpairments
887 usd
CY2022Q3 nukk Cost Method Investment
CostMethodInvestment
391217 usd
CY2023Q3 nukk Cost Method Investment
CostMethodInvestment
6602000 usd
CY2021Q4 nukk Cost Method Investment
CostMethodInvestment
6602000 usd
CY2023 us-gaap Impaired Assets To Be Disposed Of By Method Other Than Sale Amount Of Impairment Loss
ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss
6210783 usd
CY2023 us-gaap Increase Decrease In Payable For Investment Purchased
IncreaseDecreaseInPayableForInvestmentPurchased
391217 usd
CY2023Q3 us-gaap Other Investments
OtherInvestments
0 usd
CY2022Q3 us-gaap Other Investments
OtherInvestments
0 usd
CY2022 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
4310745 usd
CY2022Q3 nukk Equity Method Investment Drease Value
EquityMethodInvestmentDreaseValue
0 usd
CY2023Q3 nukk Equity Method Investment Drease Value
EquityMethodInvestmentDreaseValue
0 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11276484 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11235008 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-5539945 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-3159903 usd
CY2023Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
5703539 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
33000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8075105 usd
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2380115 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2690617 usd
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
273711 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
264224 usd
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5703539 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
13825 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
13825 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
5350 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
33000 usd
CY2023Q3 nukk Unearned Revenue
UnearnedRevenue
151617 usd
CY2022Q3 nukk Unearned Revenue
UnearnedRevenue
203222 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18255 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29133 usd
CY2023Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
169872 usd
CY2022Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
232355 usd
CY2021Q4 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
548767 shares
CY2021Q4 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
6602000 usd
CY2021Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
6602000 usd
CY2022Q1 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
5000000 usd
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
28571 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
87.5
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
138572 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.15
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
167143 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.45
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
42857 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
23.33
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
124286 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.53
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
90000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
30.5
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
34286 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.25
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0 usd
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
370878 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1913529 usd
CY2022Q1 nukk Stock Options Issued For Software Purchase
StockOptionsIssuedForSoftwarePurchase
1429 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1429 shares
CY2022Q1 us-gaap Payments For Software
PaymentsForSoftware
11237 usd
CY2023 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
3746 usd
CY2022 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
2809 usd
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
28571 shares
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
87.5
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
138572 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.15
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
58571 shares
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
44.45
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
108572 shares
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
12.25
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
74286 shares
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
15.28
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
34286 shares
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
5.25
CY2023 us-gaap Noninterest Income
NoninterestIncome
17428428 usd
CY2022 us-gaap Noninterest Income
NoninterestIncome
11845657 usd
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-665382 usd
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-977249 usd
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-225279 usd
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-330869 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-989265 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1352095 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
989265 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1352095 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.008 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.024 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.001 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.172 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.137 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.008 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.045 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.09 pure
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1726620 usd
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1129699 usd
CY2023Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
100410 usd
CY2022Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
66678 usd
CY2023Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
653976 usd
CY2022Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
549722 usd
CY2023Q3 nukk Impairment Of Digital Assetss
ImpairmentOfDigitalAssetss
1511 usd
CY2022Q3 nukk Impairment Of Digital Assetss
ImpairmentOfDigitalAssetss
169 usd
CY2023Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
123554 usd
CY2023Q3 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
612 usd
CY2023Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
364902 usd
CY2022Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
236198 usd
CY2023Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2971585 usd
CY2022Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1982466 usd
CY2023Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2971585 usd
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1982320 usd
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
146 usd
CY2022Q3 us-gaap Deferred Tax Liabilities Unrealized Currency Transaction Gains
DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
146 usd
CY2022Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
146 usd
CY2023Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
258405 usd
CY2023Q3 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0 usd
CY2022Q3 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
16691 usd
CY2023 us-gaap Other Expenses
OtherExpenses
136625 usd
CY2022 us-gaap Other Expenses
OtherExpenses
80026 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
1600000 usd
CY2023 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
1575000 usd
CY2023 nukk Provided To Related Parties
ProvidedToRelatedParties
19200000 usd
CY2022 nukk Provided To Related Parties
ProvidedToRelatedParties
19200000 usd
CY2023 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
18775000 usd
CY2022 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
18900000 usd
CY2023Q2 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
138419 usd
CY2022 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
38112 usd
CY2023Q3 us-gaap Other Receivables
OtherReceivables
2039274 usd
CY2022Q3 us-gaap Other Receivables
OtherReceivables
931136 usd
CY2023Q3 us-gaap Related Party Tax Expense Due From Affiliates Current
RelatedPartyTaxExpenseDueFromAffiliatesCurrent
229837 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6808749 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4514063 usd
CY2022Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
35000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
17500 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
17500 usd
CY2023Q3 us-gaap Investment Interest Rate
InvestmentInterestRate
0.05 pure
CY2023 us-gaap Other Income
OtherIncome
1836 usd
CY2022 us-gaap Other Income
OtherIncome
159 usd
CY2023 us-gaap Interest Income Other
InterestIncomeOther
1980 usd
CY2022 us-gaap Interest Income Other
InterestIncomeOther
159 usd
CY2023 us-gaap Proceeds Debt Securities Held To Maturity Previously Written Off Recovery
ProceedsDebtSecuritiesHeldToMaturityPreviouslyWrittenOffRecovery
299650 usd
CY2023Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
1000000 usd
CY2022 nukk Withdrawal From Line Of Credit
WithdrawalFromLineOfCredit
764892 usd
CY2023 us-gaap Line Of Credit Facility Periodic Payment Principal
LineOfCreditFacilityPeriodicPaymentPrincipal
764892 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
637072 usd
CY2023 us-gaap Line Of Credit Facility Annual Principal Payment
LineOfCreditFacilityAnnualPrincipalPayment
127820 usd
CY2023Q3 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
75619 usd
CY2023Q3 us-gaap Cash
Cash
75619 usd
CY2023Q3 us-gaap Loans Receivable With Fixed Rates Of Interest1
LoansReceivableWithFixedRatesOfInterest1
5 usd
CY2023Q3 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
75000 usd
CY2023Q3 us-gaap Cash
Cash
75000 usd
CY2023Q3 us-gaap Loans Receivable With Fixed Rates Of Interest1
LoansReceivableWithFixedRatesOfInterest1
5 usd
CY2023Q3 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
270000 usd
CY2023Q3 us-gaap Cash
Cash
270000 usd
CY2023Q3 us-gaap Loans Receivable With Fixed Rates Of Interest1
LoansReceivableWithFixedRatesOfInterest1
5 usd
CY2023 nukk Debt Instrument Outstanding Principal
DebtInstrumentOutstandingPrincipal
420619 usd
CY2023 us-gaap Interest Expense
InterestExpense
1776 usd
CY2023Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
1771 usd
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 pure
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 pure
CY2023 us-gaap Revenues
Revenues
21297642 usd
CY2022 us-gaap Revenues
Revenues
21513474 usd
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
21640783 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
22174870 usd
CY2023 us-gaap Gross Profit
GrossProfit
-343141 usd
CY2022 us-gaap Gross Profit
GrossProfit
-661396 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
17120080 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
10480928 usd
CY2023 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
34793 usd
CY2022 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-703333 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17428428 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-11845657 usd
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2380115 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2690617 usd
CY2023Q3 us-gaap Assets
Assets
3352625 usd
CY2022Q3 us-gaap Assets
Assets
18364904 usd
CY2022Q2 nukk Common Stock Amount
CommonStockAmount
75000000 usd
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
usd
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
CY2022 us-gaap Interest Expense Other
InterestExpenseOther
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.21
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.73
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
CY2022 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
usd
CY2022 nukk Proceeds From Note Receivable Related Parties
ProceedsFromNoteReceivableRelatedParties
usd
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023 us-gaap Interest Paid
InterestPaid
usd
CY2022 us-gaap Interest Paid
InterestPaid
usd
CY2023 nukk Adjustment For Common Stock Issued In Connection With Asset Acquisition
AdjustmentForCommonStockIssuedInConnectionWithAssetAcquisition
usd
CY2023 us-gaap Stock Issued1
StockIssued1
usd
CY2023 us-gaap Supplemental Deferred Purchase Price
SupplementalDeferredPurchasePrice
usd
CY2023 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
usd
CY2022Q3 us-gaap Security Deposit
SecurityDeposit
usd
CY2023Q3 nukk Customer Digital Currency Assets Current
CustomerDigitalCurrencyAssetsCurrent
usd
CY2023Q3 nukk Customer Digital Currency Liabilities Current
CustomerDigitalCurrencyLiabilitiesCurrent
usd
CY2023Q3 nukk Customer Digital Currency Assets Percentage
CustomerDigitalCurrencyAssetsPercentage
pure
CY2023 nukk Estimated Useful Life
EstimatedUsefulLife
CY2022 nukk Estimated Useful Life
EstimatedUsefulLife
CY2022Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
usd
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
usd
CY2023 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
usd
CY2022 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
pure
CY2022Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
usd
CY2022Q3 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
usd
CY2023Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023Q3 us-gaap Deferred Tax Liabilities Unrealized Currency Transaction Gains
DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
usd
CY2023Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022 us-gaap Line Of Credit Facility Periodic Payment Principal
LineOfCreditFacilityPeriodicPaymentPrincipal
usd
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001787518

Files In Submission

Name View Source Status
0001213900-24-060986-index-headers.html Edgar Link pending
0001213900-24-060986-index.html Edgar Link pending
0001213900-24-060986.txt Edgar Link pending
0001213900-24-060986-xbrl.zip Edgar Link pending
ex10-8_001.jpg Edgar Link pending
f10k2023ex10-4_nukkleusinc.htm Edgar Link pending
f10k2023ex10-5_nukkleusinc.htm Edgar Link pending
f10k2023ex10-6_nukkleusinc.htm Edgar Link pending
f10k2023ex10-7_nukkleusinc.htm Edgar Link pending
f10k2023ex10-8_nukkleusinc.htm Edgar Link pending
f10k2023ex21-1_nukkleusinc.htm Edgar Link pending
f10k2023ex31-1_nukkleusinc.htm Edgar Link pending
f10k2023ex32-1_nukkleusinc.htm Edgar Link pending
f10k2023_nukkleusinc.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
f10k2023_nukkleusinc_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
nukk-20230930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
nukk-20230930_cal.xml Edgar Link unprocessable
nukk-20230930_def.xml Edgar Link unprocessable
nukk-20230930_lab.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nukk-20230930_pre.xml Edgar Link unprocessable